about
Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationIn vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Implementation and utilization of genetic testing in personalized medicine.Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Bioinformatics and variability in drug response: a protein structural perspective.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes.Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China.Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.A physiome interoperability roadmap for personalized drug development.Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.Evaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes.Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.Pharmacogenomics and bioinformatics: PharmGKB.Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.Inhibitory Interactions of Aspalathus linearis (Rooibos) Extracts and Compounds, Aspalathin and Z-2-(β-d-Glucopyranosyloxy)-3-phenylpropenoic Acid, on Cytochromes Metabolizing Hypoglycemic and Hypolipidemic Drugs.In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity.Rapid screening for targeted genetic variants via high-resolution melting curve analysis.Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.
P2860
Q28076600-DF5F36E8-8D89-44CF-BFD8-8A75ED98C528Q33551882-4B69E374-12AD-43CC-82C7-A990C3104448Q33790423-92C64CB3-43C0-46E4-961C-B4D9053F4066Q34147916-3A8B88CF-FFE3-40EE-9040-6E76D0576269Q35612111-6578ADE4-5A2F-41FB-8C42-E661ECC086ADQ35661209-A9C34598-AFC6-48E8-89EC-35E8A8395225Q36009999-EAFEE1DC-76E8-4474-BE8C-852AFEC757E6Q36094919-25E51CD0-5605-4326-AFD5-764B5C434E59Q36104912-9903CEC3-0AD7-4D5E-B2A7-62E984196BB7Q36375432-85468248-26D4-44DF-848B-3DF7BCFE70C4Q36460560-55901C24-30AC-4BBE-B8D1-25BF34866DA8Q36487403-81D5C985-A2EE-4C30-817D-2B23D06780DDQ36596051-4381C713-1143-4D40-94BF-6DB561E20D13Q36986803-AC7418D3-807C-4C57-8215-26330B7E7C86Q37492042-687C6E99-DEFB-4CD1-A31A-D25705429859Q37552063-D43ABF98-099E-4177-B127-0414788D0423Q37590883-3F178E88-6E23-4645-B982-E104440B325FQ38705682-E71F93CF-0619-45F7-8979-41DD02560BF8Q38714565-47EDA581-BEBC-4EFE-9742-DC86B2FAA077Q38758672-1549DEF4-D4EB-4BBF-8646-C781BDCD9D98Q40161854-6DA0BAF7-7BB7-4EF3-915D-D337E77F8922Q42098029-D9691A0F-D6B0-4010-A9B1-05EE94A02D00Q42654621-5826015E-24F0-4869-9EC5-A03DC420D3FFQ45897679-14954657-8A4D-4BA5-B54B-5699FEBC291AQ46185931-86B17249-DFC7-4501-B8EC-82CFF5E3F026Q47255706-CF45B4F1-84CE-43D3-BA1E-91E1008EBFFBQ48049878-8389BA8C-B67A-475B-9169-4660FBCBFFE0Q50333604-4DEE90E8-CAD2-4331-8914-BCEFC09AED08Q54092302-9A8F48E0-038C-47EB-B453-9A16F500FF66
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytochrome P450 2C9-CYP2C9.
@en
Cytochrome P450 2C9-CYP2C9.
@nl
type
label
Cytochrome P450 2C9-CYP2C9.
@en
Cytochrome P450 2C9-CYP2C9.
@nl
prefLabel
Cytochrome P450 2C9-CYP2C9.
@en
Cytochrome P450 2C9-CYP2C9.
@nl
P2093
P2860
P1476
Cytochrome P450 2C9-CYP2C9.
@en
P2093
Derek Van Booven
Howard McLeod
Katrin Sangkuhl
Michelle Whirl Carrillo
Sharon Marsh
Teri E Klein
P2860
P304
P356
10.1097/FPC.0B013E3283349E84
P50
P577
2010-04-01T00:00:00Z